Member Info for ajithoth

I like to think of SAR as a swan, looks quiet and serene from above but below those legs are paddling away furiously. Hopefully the swan is black too.

better than your usual posts Thirdman.

https://erj.ersjournals.com/content/erj/50/1/1601953.full.pdf

the last line sums it up:
"We suggest pharmacological Tyk2 inhibition as an immune modulatory intervention strategy to sustain the crucial endogenous GM-CSF levels in severe viral/bacterial pneumonia"

also

Here we show that use of the pharmacological Tyk2 inhibitor (PRT2070) fully restored pneumococcal-induced alveolar macrophages IL-1ß and finally epithelial GM-CSF after IAV infection in human lung co-infection. This is of particular interest with regard to clinical trials in pneumonia-associated ARDS patients receiving GM-CSF treatment. The systemic administration in the trial by PAINE et al. [23] did not reveal significant effects, but a first compassionate inhalative application with a low number of cases by HEROLD et al. [22] showed positive
tendencies of pulmonary host defence modulation. If GM-CSF treatment were successful, compared to IFN receptor pathway inhibition, fewer adverse effects are likely. However, if one single factor such as GM-CSF is not sufficient to restore the entire pulmonary host defence against secondary bacterial pneumonia, an early IFN receptor pathway modulation with, for example, clinically developed Tyk2 inhibitors would offer a further promising approach, since we not only restored endogenous GM-CSF, but also demonstrated a beneficial effect of Tyk2 inhibition on reduction of bacterial growth.

frankly I'd be amazed if SAR wasn't being analysed thoroughly by a number of big pharma.

+ more good info here: https://quoteddata.com/research/sareum-holdings-tyking-nicely-2/

Hi Celtic, - yes, heres a good read about it all...
https://www.evaluate.com/vantage/articles/analysis/tyk2-reaches-tipping-point
Thoth detailed the specific differences between them all a while back - from what I remember ours is more specific (does not target JAK2 as that's bad) - has no black box warnings and has no determined MTD (maximum tolerated dose). So ours beats the other ones.

Hi Celtic - Tyk2 is a Jak....Jak actually stands for "just another kinase" - I think Tyk2 was the first to be discovered then Jak1/2/3 were discovered after. All are members of the Janus Kinase family.

indeed - and find another board to whinge on.

that makes me wonder if its Dizal Pharma that got our FLT3...

and another, apologies if posted before.
https://science.sciencemag.org/content/sci/368/6490/473.full.pdf

me too, tin foil hat on but think its from elsewhere, just detected in China first.

some chunky delayed buys in there, over £100k's worth.

I think you need to look again Fannibaws...

https://www.pharmaceutical-technology.com/news/som-biotech-covid-19-candidates/
this is interesting - they have identified prexasertib as a potential candidate - this is a CHK1 inhibitor....possibly bodes well for us.....

reminds me of that old joke...
"Right class," said the teacher. "Who can make a sentence with the word 'contagious'?"
Little Johnny threw up his hand excitedly.
"Yes, Johnny?"
"My dad saw our neighbour painting his fence with a little brush, and said, 'Blimey, that'll take the contagious!'"

Not sure if already posted but this link illustrates why we need immunomodulatory drugs that can reduce or remove respiratory distress. The vaccine could be quite a few years down the line.
https://www.fiercepharma.com/vaccines/a-bullseye-from-24-feet-covid-19-vaccine-timelines-are-overly-hopeful-analyst-says

I'll put it on 0.7 mathsprof. But all moot to me, I was never going to be selling under a penny. Like Aber, I'm either retiring in the next few years, or I'm not.

BIGHOW - we will never be involved with a vaccine, more a treatment to treat Acute Respiratory Distress\ Lung Sarcoidosis. This is the glass like appearance of the lungs that makes sufferers of the disease covid-19 need respirators and then have 50/50 odds of dying.

how are they losses if you make a gain?

haha brilliant !

that's an unfortunate misspelling!